The world's first non-hormonal targeted drug for the treatment of moderate to severe vasomotor symptoms (VMS) caused by menopause.

Vilobelimab is a monoclonal antibody that targets C5a. It is developed by InflaRx NV for the treatment of COVID-19, pyoderma gangrenosum, anti-neutrophil cytoplasmic antibody-associated vasculitis, recurrent cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, squamous cell carcinoma, pyoderma gangrenosum with vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Benegrastim is a fusion protein targeting CSF-3R (GCSFR). It is used for the treatment of neutropenia, fever, breast cancer, Parkinson's disease, and other conditions.